Older patients with IBD at higher risk for treatment failure with vedolizumab

Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists.The comparative effectiveness study, published in JAMA Network Open, also did not find any significant safety advantage with vedolizumab treatment.“There is considerable need for evidence-based treatment guidance for older patients with IBD,” Siddharth Singh, MD, MS, of the divisions of gastroenterology and biomedical informatics in the department of medicine atRead More

Generated by Feedzy